- Home
- SCYX vs VIVO Comparison
SCYX vs VIVO Comparison
Compare SCYX & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCYX | VIVO |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.0M | 37.5M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCYX | VIVO |
|---|---|---|
| Price | $0.98 | $3.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 622.3K | ★ 819.2K |
| Earning Date | 05-14-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.97 |
| 52 Week High | $1.29 | $4.27 |
Technical Indicators
Market Signals| Indicator | SCYX | VIVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.32 | 57.58 |
| Support Level | $0.73 | $1.97 |
| Resistance Level | $1.29 | $3.50 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 19.24 | 42.39 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.